Targeting cancer cells via tumor-homing peptide CREKA functional PEG nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Targeting the cell microenvironment with nanoparticle-based therapies is crucial for treating diseases.
• A key challenge in nanoparticle cancer therapy is achieving sufficient localization at the tumor site.
• Improving drug delivery vehicle recruitment to specific tumor regions can enhance therapeutic outcomes.

Purpose of the Study:

• To develop functionalized nanoparticles for improved tumor targeting and drug delivery.
• To investigate the efficacy of CREKA-functionalized polyethylene glycol (PEG) nanoparticles in cancer therapy.
• To evaluate the cellular uptake and tumor-homing capabilities of these novel nanoparticles.

Main Methods:

• Utilized a water-in-water emulsion technique to create PEG nanoparticles.
• Functionalized PEG nanoparticles with the tumor-homing peptide CREKA.
• Assessed Doxorubicin (DOX)-mediated apoptosis induction and cellular uptake via confocal microscopy.
• Measured the fibrin binding ability of the functionalized nanoparticles.

Main Results:

• CREKA-conjugated hydrogel nanoparticles demonstrated superior efficacy in inducing Doxorubicin-mediated apoptosis compared to IKVAV-conjugated particles.
• Confocal microscopy revealed significantly higher cellular uptake of CREKA-conjugated PEG particles.
• CREKA conjugation increased the fibrin binding ability of PEG particles by up to 94%.

Conclusions:

• CREKA-functionalized PEG nanoparticles offer a promising strategy for targeted cancer therapy.
• The enhanced cellular uptake and fibrin binding indicate effective tumor-homing capabilities.
• This approach holds potential for improving the therapeutic efficacy of nanoparticle-based drug delivery systems.